Marijuana Stock Movers For June 7, 2024

GAINERS: CordovaCann (OTC:LVRLF) shares closed up 25.97% at $0.07 Cansortium (OTC:CNTMF) shares closed up 14.50% at $0.15 SOL…

GAINERS:

  • CordovaCann (OTC:LVRLF) shares closed up 25.97% at $0.07
  • Cansortium (OTC:CNTMF) shares closed up 14.50% at $0.15
  • SOL Glb Inv (OTC:SOLCF) shares closed up 10.24% at $0.05
  • Indiva (OTC:NDVAF) shares closed up 6.16% at $0.03
  • CNBX Pharmaceuticals (OTC:CNBX) shares closed up 4.58% at $0.01
  • Zoned Props (OTC:ZDPY) shares closed up 4.00% at $0.65
  • Psychemedics (NASDAQ:PMD) shares closed up 3.64% at $2.25
  • Green Thumb Industries (OTC:GTBIF) shares closed up 3.40% at $12.15

LOSERS:

  • AusCann Group Holdings (OTC:ACNNF) shares closed down 20.00% at $0.01
  • Greenlane Hldgs (NASDAQ:GNLN) shares closed down 12.21% at $0.52
  • Pharmadrug (OTC:LMLLF) shares closed down 9.09% at $0.02
  • Leafbuyer Techs (OTC:LBUY) shares closed down 8.08% at $0.02
  • CLS Holdings USA (OTC:CLSH) shares closed down 7.00% at $0.05
  • Rocky Mountain High (OTC:RMHB) shares closed down 6.92% at $0.01
  • 1933 Industries (OTC:TGIFF) shares closed down 6.74% at $0.01
  • Nextleaf Solutions (OTC:OILFF) shares closed down 6.43% at $0.08
  • RIV Capital (OTC:CNPOF) shares closed down 6.26% at $0.10
  • CV Sciences (OTC:CVSI) shares closed down 5.94% at $0.09
  • Cannabix Technologies (OTC:BLOZF) shares closed down 5.64% at $0.46
  • Corbus Pharmaceuticals (NASDAQ:CRBP) shares closed down 5.30% at $44.13
  • 4Front Ventures (OTC:FFNTF) shares closed down 4.89% at $0.09
  • Aurora Cannabis (NASDAQ:ACB) shares closed down 3.83% at $5.68
  • Global Compliance (OTC:FUAPF) shares closed down 3.70% at $0.01
  • Body and Mind (OTC:BMMJ) shares closed down 3.47% at $0.05

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

AstraZeneca Announced Evusheld Long-acting Antibody Combination Recommended for Approval in the EU for the Treatment of COVID-19

AstraZeneca's Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination, has been recommended for marketing authorisation in the European Union (EU) for the treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.

AZN